Vitamin D3 for Life

Live Enlightened

Article

Vitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Full Study

Previous related pageVitamin D and Iron MetabolismNext related pageVitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Study Summary
Study at a glance

How might vitamin D affect the release of iron from cells?

This page brings together laboratory experiments and small human studies of vitamin D and iron control. Hepcidin is a hormone that reduces the release of iron from cells. It acts on ferroportin, a protein that allows iron to leave cells. Lower hepcidin may therefore make stored and recycled iron more available.

What did laboratory experiments find about vitamin D and iron release?

In human liver and immune cells grown in the laboratory, vitamin D reduced activity of the gene that makes hepcidin by about half. Tests supported a direct effect through the vitamin D receptor, which receives vitamin D signals inside cells. Ferroportin protein increased. These findings show a possible way for vitamin D to influence iron release.

How did vitamin D affect hepcidin in people?

In a small study of healthy volunteers, a single 100,000 IU dose of vitamin D2 was followed by about 34% lower blood hepcidin within 24 hours. A later trial randomly assigned 28 healthy adults to a single 250,000 IU dose of vitamin D3 or an inactive treatment. After one week, hepcidin had fallen about 73% from its starting value in the vitamin D group and was significantly lower than in the comparison group. These were research doses, not instructions for personal use.

Does lower hepcidin prove that vitamin D improves anaemia?

In the later trial, ferritin, a measure related to iron stores, and the measured signs of inflammation did not change significantly. Lower hepcidin does not prove that more red blood cells were produced or that anaemia improved. Other studies have found no benefit or results that depend on the population. Vitamin D is one influence on iron control; this evidence does not establish it as a replacement for investigating or treating iron deficiency or anaemia.

Read the full article below ↓

Iron availability is controlled not only by how much iron enters the body but also by whether stored and recycled iron can move between cells and the circulation. Hepcidin is central to that control. When hepcidin rises, it binds to the iron exporter ferroportin and reduces iron release from intestinal cells, macrophages and other iron-handling tissues. When hepcidin falls, ferroportin-mediated iron export becomes more available. Experimental and human evidence indicates that vitamin D signalling can interact directly with this hepcidin-ferroportin system, creating a mechanistic connection between vitamin D physiology and Vitamin D and Iron Metabolism. The evidence does not mean vitamin D supplementation is an iron treatment in every person, but it does show that vitamin D can participate in regulation of the machinery governing iron mobilisation. For a shorter version of this evidence review, see Vitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Study Summary.

Hepcidin controls whether iron remains trapped or becomes available

Hepcidin is a peptide hormone produced predominantly by the liver. Its physiological importance comes from its interaction with ferroportin, the major cellular iron exporter. Ferroportin allows iron to leave enterocytes after intestinal absorption and permits macrophages to return iron recovered from ageing red blood cells to the circulation. Hepcidin binding causes ferroportin to be internalised and degraded, reducing iron export.

This creates an important distinction between total body iron and circulating iron availability. A person can possess substantial iron stores while iron is functionally restricted because elevated hepcidin reduces access to those stores. Ferritin may therefore behave very differently from serum iron or transferrin saturation, particularly during inflammation. That is one reason single laboratory measurements need physiological context, a broader principle developed in What Vitamin D Levels Represent.

Hepcidin is itself regulated by several inputs. Iron loading tends to increase it. Increased erythropoietic demand tends to suppress it. Inflammation, particularly signalling involving interleukin-6, can increase hepcidin and restrict circulating iron. The inflammatory branch is therefore particularly relevant to Vitamin D and Inflammatory Signalling and to the development of anaemia of inflammation.

Vitamin D can suppress HAMP transcription

Bacchetta and colleagues investigated whether vitamin D could regulate the gene encoding hepcidin, HAMP. Their work combined human cell experiments with a small human supplementation study. In cultured hepatocytes and monocytes, treatment with either 25-hydroxyvitamin D [25(OH)D] or active 1,25-dihydroxyvitamin D [1,25(OH)₂D] reduced HAMP messenger RNA expression by approximately half.

The mechanistic experiments went further than observing an association. Promoter-reporter and chromatin-immunoprecipitation analyses supported direct transcriptional regulation involving the vitamin D receptor. Liganded VDR interacted with the HAMP promoter environment, and 1,25(OH)₂D reduced HAMP transcription. The direction differed from familiar vitamin-D-induced antimicrobial genes such as CAMP, demonstrating that VDR signalling can activate some transcriptional programmes while repressing others.

This is relevant to Vitamin D and Transcription Factors because the iron effect is not simply a downstream consequence of changing vitamin D blood levels. It involves transcriptional control of an iron-regulatory hormone. It is also consistent with the wider signalling architecture described in Vitamin D Receptors.

Suppressing hepcidin changes ferroportin biology

The cellular experiments showed a corresponding increase in ferroportin protein when HAMP expression was suppressed. Ferritin expression within cells also fell. This sequence gives the mechanism physiological coherence: lower hepcidin reduces the signal that normally limits ferroportin, allowing greater potential for cellular iron export rather than merely changing a gene without an iron-handling consequence.

That mechanism matters particularly in macrophages. A large proportion of iron required for daily erythropoiesis comes not from newly absorbed dietary iron but from macrophage recycling of iron recovered from senescent red blood cells. A pathway that changes hepcidin-ferroportin regulation therefore has the potential to alter iron availability without changing total body iron stores.

This does not imply that vitamin D is the dominant controller of ferroportin in every physiological condition. Iron status, erythropoietic demand, renal physiology and inflammatory signalling can all exert powerful effects. Vitamin D should therefore be treated as one regulator within the iron-control network rather than as an overriding switch.

A human pilot study showed a rapid fall in circulating hepcidin

The same research programme included healthy volunteers who received a single oral dose of 100,000 IU vitamin D₂. Mean circulating 25(OH)D increased from approximately 27 ng/mL before supplementation to 44 ng/mL afterwards. Within 24 hours, circulating hepcidin had fallen by approximately 34%.

The rapid timing is useful because it is compatible with a regulatory response rather than a slow correction of iron stores. The result does not prove that iron delivery to the bone marrow increased sufficiently to change haemoglobin, because those downstream endpoints were not established by this short experiment. It demonstrates that changing vitamin D exposure can be followed rapidly by a measurable change in an iron-regulatory hormone.

The distinction between a mechanistic biomarker and a clinically meaningful downstream effect is central to Vitamin D Status vs Vitamin D Effect. A fall in hepcidin may alter the regulatory environment, but whether haemoglobin, iron stores or symptoms change depends on what limits erythropoiesis in the individual.

A randomized high-dose trial reproduced hepcidin suppression

A later pilot randomized, double-blind, placebo-controlled trial tested a single 250,000 IU dose of vitamin D₃ in 28 healthy adults. More than 70% of participants were vitamin D deficient at baseline. One week after dosing, plasma hepcidin had fallen by approximately 73% from baseline in the vitamin-D group. The placebo group did not show a statistically significant change.

The between-group comparison at one week was also significant, with geometric mean hepcidin concentrations of approximately 2.4 ng/mL in the vitamin-D group and 9.0 ng/mL in placebo. This strengthens the argument that the earlier observation was not merely a transient uncontrolled association.

However, ferritin did not change significantly. Neither did the measured inflammatory cytokines IL-1β, IL-6, IL-8 or MCP-1. This is scientifically useful because it separates several possible mechanisms. Hepcidin suppression occurred without detectable short-term reduction in those measured inflammatory markers and without measurable depletion of ferritin stores.

Direct hepcidin regulation can be separated from general anti-inflammatory effects

Inflammation is a major hepcidin stimulus, so one possible explanation for lower hepcidin after vitamin D would be that vitamin D first reduced inflammation and hepcidin then fell secondarily. The randomized healthy-adult study did not support that simple sequence over one week because hepcidin changed while the measured cytokines did not.

That does not mean inflammation is irrelevant. In chronic inflammatory disease, vitamin D, cytokines and hepcidin can interact simultaneously. Rather, the trial suggests that vitamin D-mediated hepcidin regulation is not necessarily dependent on a preceding measurable fall in systemic inflammatory cytokines. The inflammatory pathway remains an additional layer, particularly in the territory covered by Vitamin D and Chronic Inflammation.

25(OH)D and 1,25(OH)₂D perform different evidential roles

Interpretation also requires care over which vitamin D metabolite is being discussed. Routine vitamin D status is generally assessed with circulating 25(OH)D. The transcriptional mechanism, however, is mediated through active vitamin-D signalling involving VDR and 1,25(OH)₂D. Cells capable of local activation may therefore experience signalling conditions that are not represented perfectly by a single circulating 25(OH)D value.

This distinction is developed in Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D. The iron evidence should not be interpreted as though a particular 25(OH)D concentration automatically predicts a fixed amount of hepcidin suppression.

Why reduced hepcidin does not guarantee correction of anaemia

Haemoglobin production depends on more than iron release. Bone-marrow function, erythropoietin, renal function, inflammation, actual iron stores, folate and vitamin B12 status, blood loss and many disease-specific factors can determine whether additional available iron becomes new red-cell mass.

Consequently, hepcidin suppression is a mechanistically important intermediate endpoint rather than proof that vitamin D supplementation will correct anaemia. Later intervention studies in chronic kidney disease and older populations have produced null or context-dependent results for haemoglobin and iron biomarkers. Those findings do not invalidate the hepcidin mechanism; they define its physiological limits.

The broader pattern is consistent with Vitamin D Response: a real molecular response can occur without producing the same whole-body outcome in every population. Disease state can alter what step in the pathway is actually limiting.

What this evidence establishes

The strongest conclusion is that vitamin D signalling can regulate the hepcidin-ferroportin axis. Experimental evidence supports direct repression of HAMP transcription through VDR-related mechanisms. Lower HAMP expression is associated with greater ferroportin protein. Human supplementation studies show rapid reductions in circulating hepcidin after high-dose vitamin D exposure.

The evidence does not establish that vitamin D is universally capable of mobilising enough iron to improve haemoglobin, that vitamin D deficiency is a primary cause of iron deficiency, or that supplementation should replace investigation and treatment of established iron deficiency or anaemia.

For the integration of this mechanism with inflammatory anaemia and the contrasting clinical-trial evidence, see Vitamin D, Hepcidin, Iron Availability and Anaemia: Evidence Synthesis.

Scientific sources

Adriana Bacchetta and colleagues. Suppression of iron-regulatory hepcidin by vitamin D. Journal of the American Society of Nephrology. PMID: 24204002.

Jessica A Alvarez and colleagues. High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. Clinical Nutrition. PMID: 27402475.

Related reading

Original sources